XERS Xeris Biopharma Holdings Inc.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.

Recent Analyst Ratings for Xeris Biopharma Holdings Inc.

Date	Price Target	Rating	Analyst
11/11/2024	$3.00	Overweight → Neutral	Piper Sandler
3/28/2024	$5.00	Outperform	Oppenheimer
8/28/2023	$4.50	Buy	Craig Hallum
10/21/2022	$4.00	Buy	Jefferies
4/28/2022	$6.50	Buy	Craig Hallum
2/16/2022	$8.00 → $6.00	Outperform	SVB Leerink
12/31/2021	$6.00 → $8.00	Outperform	SVB Leerink
12/31/2021	$4.25 → $5.40	Buy	HC Wainwright & Co.
11/17/2021	$6.00	Outperform	SVB Leerink
10/29/2021	$4.00	Buy	HC Wainwright & Co.

See more ratings

Xeris Biopharma Holdings Inc.

Peers

Recent Analyst Ratings for Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Mcculloch Kevin bought $109,475 worth of shares (25,000 units at $4.38), increasing direct ownership by 1% to 1,708,585 units (SEC Form 4)

Director Bormann-Kennedy Barbara-Jean Anne was granted 50,000 shares, increasing direct ownership by 47% to 157,500 units (SEC Form 4)

Director Persky Marla was granted 50,000 shares, increasing direct ownership by 47% to 157,500 units (SEC Form 4)

Director Halkuff Dawn was granted 50,000 shares, increasing direct ownership by 47% to 157,500 units (SEC Form 4)

Director Sherman Jeffrey W was granted 50,000 shares, increasing direct ownership by 30% to 214,380 units (SEC Form 4)

Director Johnson John was granted 50,000 shares, increasing direct ownership by 6% to 940,983 units (SEC Form 4)

Director Kong Garheng was granted 50,000 shares, increasing direct ownership by 30% to 214,144 units (SEC Form 4)

Officer Mcculloch Kevin covered exercise/tax liability with 733 shares, decreasing direct ownership by 0.04% to 1,683,585 units (SEC Form 4)

Director Brady James Aloysius was granted 100,000 shares (SEC Form 4)

SEC Form 3 filed by new insider Brady James Aloysius